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Cell-free DNA (cfDNA) has significant potential in the diagnosis and monitoring of clinical 
conditions. However, accurately and easily distinguishing the relative proportion of DNA 
molecules in a mixture derived from two different sources (i.e., donor and recipient 
tissues after transplantation) is challenging. In human cellular transplantation, there 
is currently no useable method to detect in  vivo engraftment, and blood-based non- 
invasive tests for allograft rejection in solid organ transplantation are either non-specific 
or absent. Elevated levels of donor cfDNA have been shown to correlate with solid organ 
rejection, but complex methodology limits implementation of this promising biomarker. 
We describe a cost-effective method to quantify donor cfDNA in recipient plasma using 
a panel of high-frequency single nucleotide polymorphisms, next-generation (semicon-
ductor) sequencing, and a novel mixture model algorithm. In vitro, our method accurately 
and rapidly determined donor:recipient DNA admixture. For in vivo testing, donor cfDNA 
was serially quantified in an infant with a urea cycle disorder after receiving six daily infu-
sions of donor liver cells. Donor cfDNA isolated from 1 to 2 ml of recipient plasma was 
detected as late as 24 weeks after infusion suggesting engraftment. The percentage 
of circulating donor cfDNA was also assessed in pediatric and adult heart transplant 
recipients undergoing routine endomyocardial biopsy with levels observed to be stable 
over time and generally measuring <1% in cases without moderate or severe cellular 
rejection. Unlike existing non-invasive methods used to define the proportion of donor 
Abbreviations: ACR, acute cellular rejection; AMR, antibody-mediated rejection; BAQ, base alignment quality; cfDNA, 
cell-free DNA; EMB, endomyocardial biopsy; gDNA, genomic DNA; HT, heart transplant; NSA, no shared alleles; OEM, 
original equipment manufacturer; OSA, one shared allele; OTC, ornithine transcarbamylase deficiency; SD, standard deviation; 
SNPs, single nucleotide polymorphisms; SOT, solid organ transplant; WGS, whole-genome sequencing.
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cfDNA in solid organ transplant patients, our assay does not require sex mismatch, 
donor genotyping, or whole-genome sequencing and potentially has broad application 
to detect cellular engraftment or allograft injury after transplantation.
Keywords: cell-free Dna, transplantation, hepatocyte transplantation, heart, solid organ transplantation, 
biomarker
inTrODUcTiOn
The diagnosis of allograft rejection prompts an immediate change 
in management and is strongly associated with adverse outcomes. 
The gold standard for the detection of solid organ transplant 
(SOT) rejection requires tissue biopsy and histologic evaluation. 
However, this approach has significant limitations including the 
logistics of organizing the biopsy at short notice and risks associ-
ated with an invasive procedure. Non-invasive tests are safer and 
allow for more frequent monitoring, but current tests are generally 
too non-specific or insensitive for reliable rejection monitoring (1).
Allogeneic hepatocyte transplantation is emerging as a suc-
cessful strategy to bridge patients to liver transplant in metabolic 
diseases (2). This approach is particularly useful in small infants 
where liver transplantation is not immediately feasible due to 
size and increased risk of technical complications. The principal 
assay to measure engraftment in liver cell transplantation (e.g. 
for urea cycle disorders) measures the conversion of 13C-acetate 
to 13C-urea (3), but this does not directly assess whether healthy 
donor cells are present. There is currently no acceptable, non-
invasive method for the in vivo detection of donor cells that is 
useable in humans.
Cell-free DNA (cfDNA) is released primarily during cellular 
apoptosis and is found in the blood of all individuals (4–6). 
In the transplanted patient, cfDNA is derived from both recipi-
ent tissues and the donated organ or cells. Methodologies have 
been developed to quantify levels of donor-derived cfDNA in 
SOT with elevated levels associated with allograft injury from 
rejection or infection (7–14). Although promising, these studies 
required a  priori knowledge of donor and recipient genotypes, 
donor–recipient sex mismatch, use of whole-genome sequencing 
(WGS), or the targeted amplification or sequencing of propri-
etary polymorphic markers or genomic regions. These issues 
represent significant barriers to the widespread use of cfDNA as 
a biomarker in transplantation.
We have developed an approach that does not require separate 
donor and recipient genotyping or WGS and can be completed 
rapidly using small volumes of plasma collected from the cellular 
or SOT recipient. We demonstrate our validation of this assay 
in vitro and its utility in the first application of cfDNA to meas-
ure the presence of donor cells in a human liver cell transplant 
recipient and for the quantification of donor-derived cfDNA in 
pediatric and adult heart transplant (HT) recipients.
MaTerials anD MeThODs
Patient information
This study was approved by the Conjoint Health Research Ethics 
Board at The University of Calgary (study ID REB14-1244). 
There were two distinct clinical patient scenarios. For the first 
application, the patient was a male infant with X-linked ornithine 
transcarbamylase deficiency (OTC) due to a deletion of exons 
1–10 of the OTC gene. His peak ammonia in the first week of 
life was 1,368 μmol/l (normal <50 μmol/l). At 6 months of age, 
he received donor hepatocytes (0.3  ×  109 viable human liver 
cells per kilogram) from a single source via a portal venous 
catheter for six consecutive days using a protocol identical to the 
CCD05 trial (Cytonet GmbH & Co., KG, Weinheim, Germany). 
Approximately 20  days after the completion of the liver cell 
infusions, his ammonia had normalized to less than 50 μmol/l. 
Peripheral blood was drawn prior to the infusion of the donor 
liver cells and at 1 week (1 day after the 6th infusion), 1, 3, and 
6 months post-infusion. The patient was ultimately bridged to a 
successful liver transplant at 16 months of age.
The second application involved blood collection from 
pediatric and adult HT recipients at the time of a clinically 
indicated endomyocardial biopsy (EMB). In children, EMB 
was performed at 1, 6, and 12 months post-HT and then annu-
ally up to 5 years. In adults, EMB was performed weekly for 
1  month starting at 2  weeks post-HT then every 2–4  weeks 
until 6 months and then at 9, 12, 18, and 24 months. Five tissue 
samples were obtained from the right ventricular surface of the 
septum, stained with hematoxylin and eosin, and evaluated for 
acute cellular rejection (ACR) using light microscopy. Tissue 
samples were also evaluated for the presence of antibody-medi-
ated rejection (AMR) by C4d-positive immunohistochemical 
staining. Biopsy findings of ACR or AMR were reported by 
the responsible pathologist (not involved in the study) using 
standard criteria (15, 16). Non-transplant controls were healthy 
volunteers.
isolation of Plasma cell-Free Dna
After obtaining informed consent, whole blood (2–10  ml) 
was collected from patients in cfDNA blood collection tubes 
(Streck). Blood was centrifuged at either 4,000  rpm (larger 
volumes) or 13,000 rpm (smaller volumes) at 4°C for 15 min, 
the plasma removed, and centrifuged again at 13,000  rpm at 
4°C for 15 min and the supernatant frozen at −80°C until used. 
Cell-free DNA was isolated from 1 to 4 ml of thawed plasma 
using the QIAamp Circulating Nucleic Acid kit (Qiagen). 
Isolated cfDNA was quantified using a Qubit fluorometer (Life 
Technologies), and purity (absence of nuclear DNA) was con-
firmed using a TapeStation 2200 D1000 tape (Agilent). In the 
case of contaminating genomic DNA, a size selection step was 
incorporated into our protocol to isolate fragmented cfDNA of 
100–300  bp using magnetic SPRIselect or AMPure XP beads 
(Beckman Coulter).
FigUre 1 | Diagram of the admixture theory underlying our algorithm. 
When donor and recipient alleles are identical (AA), the signal represents the 
theoretical error rate for base calling (0.001 or 0.1% from the BAQ score of 
30). The dotted lines demonstrate the pooled estimate of error rates across 
samples. When there is one shared allele (AB), then the % donor (x) is equal 
to x/2 for n number of sites (where n generally equals 42). When there are no 
shared alleles (BB), then the number of SNPs is equal to x.
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library Preparation and sequencing
Barcoded sequencing libraries were prepared using size-selected 
cfDNA (1  ng) and the HID-Ion Ampliseq Identity Panel and 
Ampliseq Library kits (ThermoFisher Scientific). The HID-Ion 
Ampliseq Identity Panel that we used contained 124 SNPs on 
the autosomal and Y chromosomes curated from the literature 
(17–19) and designed for forensic analyses from degraded 
samples. Libraries were quantified using Qubit and TapeStation 
assays, diluted to 20  pM, pooled, and then put on the Ion 
Torrent OneTouch 2 system (ThermoFisher Scientific) for the 
creation of template beads. Beads were loaded onto an Ion 316 
or 318 semiconductor chip for sequencing on the Ion Torrent 
PGM platform (ThermoFisher Scientific) in 200 bp mode. The 
original equipment manufacturer (OEM) base caller with default 
parameters was used, and resultant sequences were mapped to 
the GRCh37 reference sequence using the OEM tmap software 
in stage1/map4 mode.
Modeling Donor–recipient cfDna 
admixture
Biallelic autosomal loci from the Human Identity Panel homozy-
gous in the major (“recipient”) sample contributor were selected. 
A locus was considered homozygous if the variant was present in 
>86% of the sequence reads with base quality scores ≥30. Loci 
with >5% ambiguous base calls were excluded. Non-consensus 
data (minor base calls) at recipient homozygous loci were then 
collectively used to estimate the minor (“donor”) contribu-
tion through a statistical procedure known as Finite Mixture 
Modeling with linear constraints. For a human sample with two 
contributors, biology dictates that the donor model should have 
three non-consensus signals: (1) both alleles same as recipient 
25% of the time, (2) one allele same as recipient 50% of the 
time, and (3) neither allele same as recipient 25% of the time 
(Figure 1). The “normalmixEM” method from the open source 
R package “mixtools” was used to generate the models (20). 
Mixture modeling requires simulation and, therefore, can yield 
different results for the same input data on different software 
runs. The mean and SD of 10,000 simulations were taken as the 
final result, and the overall calculation was completed in few 
minutes. Using a base alignment quality (BAQ) score (Phred-
like score) of Q30 gives us a theoretical error rate of 0.001. 
A pooled estimate of error rate was calculated using all samples 
run on the same chip.
Biologically relevant constraints were added to improve the 
estimates and yield consistent results between runs. Since the 
panel consists of independent evenly biallelic loci, a 1:2:1 inten-
sity ratio for the three donor cfDNA signals was used, i.e., same 
alleles as recipient (signal = error rate), one shared allele (OSA), 
and no shared alleles (NSA). An initial estimate of 0.1% for the 
mean of the error rate was provided, based on the base quality 
cutoff (BAQ score of 30 = 0.1% error rate). A 1:2 ratio constraint 
for the means of the OSA and NSA was enforced. A 1:2 constraint 
for the OSA:NSA SDs was also employed. For each simulation, 
the final estimate of donor cfDNA contribution consists of the 
NSA%, minus the final error estimate. For our data, the Gaussian 
(“normal”) distribution yielded more accurate results than the 
gamma distribution or other methods available in the mixtools 
package.
To test our algorithm, HapMap DNA samples (Coriell 
Institute for Medical Research) were used to simulate a mixture 
of two separate populations as previously described (9) with 
sample NA07348 designated as the “recipient” and NA10830 as 
the “donor.” Six mixtures (total of 1 μg for each mixture) were 
created with increasing concentrations of NA10830 (0, 0.5, 1, 2, 
4, and 8%). Concentrations were chosen based on data suggesting 
that donor cfDNA is present at baseline between 0 and 1% and 
increases with rejection to at least 3–6% in heart transplantation 
(9). We prepared libraries of these six genomic (gDNA) mixtures 
in triplicate and sequenced them as described above.
statistical analysis
Data are shown as means ±  SD. Calculations were performed 
in Excel (Microsoft Corporation) for calculation of the linear 
correlation between the expected and measured donor gDNA 
concentrations, and the Student’s t-test was used to determine if 
there was a significant difference (defined as p < 0.05) between 
sample groups.
resUlTs
We began by replicating previous work (9) using two gDNA sam-
ples and WGS (SOLiD platform, Applied Biosystems) to detect 
increasing amounts of one sample in a mixture. We were suc-
cessful in replicating this part of the study from Snyder et al. (9) 
and found a strong (R2 = 0.98) correlation between the expected 
and measured donor DNA concentrations (data not shown) but 
were dismayed by the cost, inefficiency, and complex bioinfor-
matics required for this assay. We then developed an alternative 
FigUre 2 | In vitro assay validation. Results for semiconductor sequencing of six separate genomic DNA mixtures (0, 0.5, 1, 2, 4, and 8%) with strong 
correlation (R2 = 0.97) between the expected (actual) and observed (measured) levels of donor cfDNA as calculated by our algorithm. The experiment was 
performed in triplicate with each individual admixture result plotted.
Table 1 | comparison of sequencing platforms for the measurement of 
donor cfDna.
item ion Torrent Wgs (illumina)
Sequencing overview Ion 316 chip v2  
(200 bp reads)
Paired end (2 × 150 bp)
Library overview AmpliSeq Identity Panel  
(124 SNPs)
DNA fragment library  
(3 Gb genome)
Expected output 300–600 Mb 100–120 Gb
Expected reads 2–3 million 800 million
Coverage per SNP ≥1000 ≥30
Cost of library 
preparation
$255 $85
Sequencing cost $700 $6670
Turnaround time 3 days 3 days
Samples per run 8 1
Total cost per sample $163.13 $6755
With the ability to accommodate multiple samples per sequencing run due to the lower 
required output, the Ion Torrent platform is more cost-effective compared to WGS.
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methodology that we tested using identical mixtures of HapMap 
gDNA. We were also able to accurately detect increasing amounts 
of an individual sample in a mixture and at a fraction of the cost 
of the WGS method (Table 1). There was strong (R2 = 0.97) zero-
intercept linear correlation between the expected and measured 
donor DNA concentrations over three independent replicates 
(Figure 2).
Although smaller blood volumes (2–5 ml) were often collected 
(due to small patient size and pediatric blood volumes) in Streck 
tubes designed for larger blood volumes (10 ml), we were able to 
successfully isolate cfDNA in all cases. Different centrifugation 
speeds for the separation of plasma from whole blood were tested 
with equivalence in cfDNA yield (data not shown). Of five kits 
tested, greatest and most reliable yields of cfDNA from plasma 
were obtained using the QIAamp Circulating Nucleic Acid kit 
(data not shown). In our initial experiments, contaminating 
gDNA complicated estimates of cfDNA yield (particularly with 
smaller volumes of blood), and we added a size-selection step 
(Figure  3) before proceeding onto library construction. This 
process was successfully used to isolate cfDNA from all patient 
plasma samples with sufficient material recovered to generate 
acceptable sequencing libraries. As shown in Figure 4, estimates 
of donor DNA plateaued at approximately 1200–1500 reads per 
base. Since approximately 300–600 Mb of sequencing reads can 
be obtained using the 316 PGM chip, we used up to eight indi-
vidual samples per chip.
Detection of infused Donor liver cells
In our infant with OTC deficiency, donor cfDNA was quantified 
prior to the infusion of donor hepatocytes and at serial time 
points post-infusion to provide a measure of engraftment success 
(Figure 5). There was a large initial surge in the amount of donor 
cfDNA detected at week 1 (1 day after the 6th liver cell infusion), 
at 1-month post-infusion, and then the levels steadily declined. 
At 3 months post-infusion, we failed to detect any donor cfDNA 
in the single sample that was collected (despite successful isola-
tion of cfDNA from the plasma), but donor cfDNA was detectable 
in the subsequent sample at 6 months post-infusion.
Detection of Donor cfDna in heart 
Transplantation
We also applied our novel assay to plasma collected from healthy 
non-transplant controls (to estimate background in our assay due 
to the error rate for base calling) and from pediatric and adult 
FigUre 3 | removal of contaminating nuclear Dna from plasma using size selection. (a) Example of plasma cfDNA (100–200 bp) preparation containing 
larger fragments (>500 bp) of genomic DNA. (b) Contaminating gDNA was removed by incorporating a size-selection step prior to library construction. L, ladder; 
1–3, plasma cfDNA samples. Green (minimum) and purple (maximum) lines indicate the sizing range of the assay.
FigUre 4 | effect of increasing read depth on proportion estimates. Using genomic DNA mixtures (0, 1, 2, 4, and 8%), we see that for an individual sample, 
read depth >1200–1500 is associated with reduced error estimate for the proportion of donor cfDNA present. Fewer reads are associated with decreased 
confidence in the estimate for the proportion of donor cfDNA. Data are based upon sequencing of individual admixtures performed in triplicate.
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HT recipients undergoing a clinically indicated EMB. Relatively 
low levels of plasma donor cfDNA were seen for all pediatric HT 
patients, as expected, since all patients were asymptomatic with 
no evidence of dysfunction by echocardiography, and none had 
evidence of significant ACR or AMR by EMB with all graded 
as ACR 0R and pAMR 0 according to ISHLT grading criteria 
(15, 16). However, as a group, the levels of donor cfDNA were 
significantly higher (p = 0.02 by Student’s t-test) than background 
FigUre 5 | levels of donor cfDna pre- and post-liver cell transplantation. The percentage of donor cfDNA present in the blood of a single patient with 
X-linked ornithine transcarbamylase deficiency both before ( −1 week) and at 1, 4, 12, and 24 weeks after the initiation of donor hepatocyte infusions. Donor cfDNA 
was not detectable by our assay pre-infusion or at 12 weeks post-transplant. The percentage of donor cfDNA is shown for each group ±SD.
FigUre 6 | levels of donor cfDna in plasma from healthy pediatric heart transplant patients. Percentage of donor cfDNA present in non-transplant 
controls (C1–5, representing background noise or error) and in healthy pediatric heart transplant patients (HT1–4) free of rejection (ACR 0R and pAMR 0) or allograft 
dysfunction who underwent routine surveillance endomyocardial biopsies. The percentage of donor cfDNA is shown for each group ± SD. Comparing average levels 
for the two groups, the amount of donor cfDNA in transplant patients is significantly elevated above background controls (p = 0.02).
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control levels (Figure 6). In the samples collected from adult HT 
recipients, we did not find a statistically significant difference 
(p = 0.7) between pooled donor cfDNA levels in patients with 
ACR 0R (n =  15) or 1R (n =  24) and who were free of AMR 
(Figure  7). In serial samples collected from individual adult 
patients undergoing routine protocol EMB post-HT, we saw that 
levels of cfDNA generally remained low (<1%) and stable post-
transplant (representative example shown in Figure 8).
FigUre 7 | levels of donor cfDna in plasma from adult heart transplant patients without significant rejection. No significant difference (p = 0.7) was 
detected between levels of donor cfDNA from adult heart transplant recipients with none (ACR 0R, n = 15) or mild (ACR 1R, n = 24) cellular rejection on routine 
endomyocardial biopsy. The percentage of donor cfDNA is shown for each group ± SD.
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DiscUssiOn
We began by replicating previous work using gDNA and WGS to 
detect increasing amounts of one DNA sample in a mixture (9). 
Based on our experience, we developed an alternative methodol-
ogy that used the Ion PGM semiconductor sequencing platform 
to sequence a commercially available panel of 124 highly poly-
morphic SNPs originally developed for the forensic identification 
of individual DNA samples. Relatively deep sequencing (at least 
1200-fold coverage) of selected high-quality autosomal SNPs 
(on average 42 SNPs) combined with a novel and biologically 
relevant statistical model enabled us to non-invasively, rapidly, 
and accurately quantify the proportion of donor alleles from a 
small sample of recipient plasma.
The clinical benefit of liver cell infusion as a bridge to 
transplantation for metabolic liver disease has been established. 
However, a direct, non-invasive, and clinically useful method 
for the detection of donor cell engraftment in the recipient is 
not available. Our assay provided a direct measure of donor 
hepatocyte cfDNA, which correlated with improved ammonia 
control in this patient and, therefore, likely represented mate-
rial from engrafted liver cells. In our patient, we saw a rapid 
FigUre 8 | stable serial cfDna levels post-transplantation for a single adult heart transplant recipient. Samples were taken at the time of routine 
post-transplant surveillance endomyocardial biopsies from 23 to 183 days post-transplant, and all were free of serious rejection and reported as either no (0R) or 
mild (1R) ACR with no evidence of AMR. The percentage of donor cfDNA is shown for each time point with error estimates as SD.
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increase in the percentage of donor cfDNA detected at 1-week 
post-infusion. This may represent the early death of donor cells 
that do not successfully engraft and is analogous to the elevated 
levels of donor cfDNA seen early post-heart or lung transplanta-
tion (7, 21). Levels of donor cfDNA had begun to decline by 
1-month post-infusion, and at 3 months post-infusion, we did 
not detect any donor cfDNA. The lack of cfDNA at week 12 was 
a single measure and may be primarily due to sample collection 
that took place after >12 h of hemodiafiltration treating a tem-
porary episode of hyperammonemia. Kohlova and colleagues 
demonstrated that cfDNA levels increased after hemodialysis 
(22), but these were stable renal failure patients undergoing 
routine hemodialysis, which likely would not have dialyzed 
cfDNA. In our patient, the hyperammonemia required aggres-
sive hemodiafiltration, which can remove larger molecules (23) 
and could have removed the cfDNA. Alternatively, given that 
just a single sample was obtained, this could represent an error 
in our methodology. However, we obtained a similar result from 
repeat sequencing of the library. When sample collection was 
repeated at 24  weeks post-liver cell infusion, we ensured that 
>72 h had passed from the time of hemodiafiltration, and this 
sample indeed showed that donor liver cells were still present in 
the recipient. Therefore, the sustained detection of donor cfDNA 
at 4 and 24 weeks post-liver cell infusion in our patient receiv-
ing concomitant immunosuppression likely reflects sustained 
engraftment of donor liver cells. In animal studies, hepatocytes 
were found engrafted in the liver and spleen (24) within 1 week 
of liver cell infusion, and in humans with acute liver failure, 
engrafted liver cells were found at 14 days post-liver cell infusion 
by biopsy (25). In the future, examination of the recipient liver 
at the time of transplantation could allow this to be confirmed 
although the size of the recipient liver, and the relatively sparse 
number of donor cells makes this potentially difficult.
In our cohort of pediatric HT recipients, we demonstrated that 
low levels of donor cfDNA (generally <1%) can be detected in the 
absence of allograft dysfunction or rejection, but that these levels 
are distinct from non-transplant controls where the presence of 
“donor” cfDNA represents the error rate for base calling. Using 
our assay, we found that levels of donor cfDNA from adult HT 
recipients with either no (ACR 0R) or mild (ACR 1R) rejection do 
not differ significantly. This finding is consistent with the clinical 
practice of treating ACR 0R and 1R as equivalent and generally 
not altering management or increasing immunosuppression.
One concern regarding the use of donor cfDNA as a biomarker 
is that levels of cfDNA in an individual may fluctuate over time. 
Changes in total circulating cfDNA have been documented after 
extreme exercise, trauma, or infection (26–28) but, we found 
that, for a transplant patient who is clinically well, serial levels 
of donor cfDNA appear to be relatively stable. The proportion of 
donor cfDNA is likely to increase in other instances of allograft 
injury including cardiac allograft vasculopathy (11) and BK virus 
nephropathy (10), but further characterization of the donor 
cfDNA molecules released from the injured allograft may provide 
insight into the mechanism underlying allograft injury and may 
provide specificity for this sensitive biomarker. This may provide 
cfDNA with advantages not available for the non-specific circulat-
ing biomarkers currently used in kidney or liver transplantation.
Due to the numerous benefits a non-invasive test for rejec-
tion would provide many potential blood biomarkers have been 
tested but with little success (1). However, donor cfDNA is a 
promising new candidate and may more reliably reflect allograft 
health, since it is directly derived from the transplanted cells or 
organ (29). Unfortunately, quantification of donor cfDNA using 
WGS is limited by expense, the need for a priori genotyping and 
complex bioinformatics. Other methods to measure cfDNA are 
limited by the requirement for donor–recipient sex mismatch, 
independent donor and recipient genotyping or proprietary 
components (8, 10–12). Our assay facilitates potential clinical 
applicability by using a readily available panel of SNPs and 
an algorithm that removes the need for donor and recipient 
genotyping. Furthermore, since fewer reads are required to 
distinguish between donor and recipient molecules, we are able 
to use a less expensive platform, which can complete the required 
sequencing within 4 h. This rapidity enables our assay to poten-
tially compete with the time required for routine clinical biopsy 
interpretation. Currently, an individual technician can prepare 
8–16 sample libraries per day, and automation may increase 
this number. Although we used semiconductor sequencing, the 
principle of this assay and the algorithm can be used with any 
high-throughput platform, because noise estimation is indepen-
dently performed for each sequencing run. Issues with sampling 
error related to the small number of molecules sampled may be 
mitigated by increasing panel size, an option not readily available 
for alternative, targeted approaches (8).
limitations
There are several limitations to our approach. Our assay does 
not assess the functional health of the engrafted cells and clinical 
correlation (e.g., levels of ammonium, need for dialysis) is still 
required. Similarly, information collected reflects only allograft 
engraftment/health, and we do not obtain additional informa-
tion regarding the presence of circulating viruses, which may 
be diagnostically useful or helpful in estimating an individual’s 
degree of immunosuppression (21, 30). With our algorithm, there 
are several assumptions made. We are limited to situations where 
the donor fraction is <14%. However, based on published reports 
of allograft rejection in patients >14 days post-transplant demon-
strating levels of donor-derived cfDNA generally <10% (7, 14), 
we feel that our assay still has utility in the detection of rejection 
in stable SOT patients who are further out from transplanta-
tion – arguably, the population where a non-invasive method 
to diagnose allograft dysfunction is most needed and useful. 
However, this may only be optimal for surveillance post-heart 
transplantation and may be inappropriate for other organs (e.g., 
lung and liver) where the percentage of circulating donor cfDNA 
can be substantially higher (21). These organ-specific differences 
may make optimization of our assay for individual organs/cells 
necessary. Furthermore, since our assay relies upon differences 
in minor allele frequency between individuals, our assay is likely 
not useful for closely related donor–recipient pairs as seen after 
living-related kidney donation. In our early experience, we found 
that measures of cfDNA quantity after isolation were frequently 
over-estimated related to the presence of nuclear genomic DNA 
from white blood cells contaminating our plasma preparations, 
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